DISCOVER: More Favorable Renal and Bone Outcomes With FTC/TAF vs FTC/TDF for HIV PrEP Through 96 Wks

March 8-11, 2020; Boston, Massachusetts
Longer-term follow-up demonstrates continued noninferior efficacy and more favorable bone and renal safety profile of FTC/TAF vs FTC/TDF for HIV prevention in MSM and transgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: March 15, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Related Content

Dr William R. Short: key considerations for the use of long-acting cabotegravir and rilpivirine in pregnancy, from Clinical Care Options (CCO)

William R. Short, MD, MPH, AAHIVS Released: September 28, 2022

An expert panel of healthcare professionals and patient advocates discuss barriers faced by aging patients with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Melanie Reese Marc Thompson
Released: September 23, 2022

Expert selections of cutting-edge HIV data, including the latest on long-acting therapies and pre-exposure prophylaxis

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Darcy Wooten, MD
Released: September 23, 2022

Expert analysis of barriers and solutions to PrEP uptake in key populations

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: September 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings